Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison, Alessandro Maria Vannucchi, Uwe Platzbecker et al. · The Lancet Haematology · 2017
Cited by 321 works. doi:10.1016/s2352-3026(17)30237-5
Authors
- Claire N. Harrison
- Alessandro Maria Vannucchi
- Uwe Platzbecker
- Francisco Cervantes
- Vikas K Gupta
- David Lavie
- Francesco Passamonti
- Elliott F. Winton
- Hua Dong
- Julia D. Maltzman
- Jean‐Jacques Kiladjian
- Srđan Verstovšek
References
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients